CSI Market
Sign In | Register

Lumos Pharma Inc (LUMO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access LUMO quarterly Cash Flow →
Examining cash flow movements between Lumos Pharma Inc and Dec 31 2019 reveals how Dec 31 2023 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Dec 31 2022) (Dec 31 2021) (Dec 31 2020) (Dec 31 2019)
Operating Activities
Income-34.03
Depreciation & amortization0.04
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation2.32
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Debt Instrument Decrease Forgiveness-
Forgiveness Of Notes Receivable From Related Parties-
Increase Decrease In State Research And Development Credit Receivable-
Preferred Stock Accretion Of Redemption Discount-
Capital Expenditures Incurred But Not Yet Paid-
Stock Issued-
Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.01
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.27
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.68
Other Working Capital0.00
Other Noncash Income-0.39
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-31.10
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-7.38
Real Estate Investments0.00
Proceeds From Maturities Of Marketable Securities18.12
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired in Excess of Payments to Acquire Business0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses and Interests in Affiliates0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities10.74
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1.28
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-56.03
Repayments Advances Of Notes Receivable For Common Stock-
Proceeds From Subsidiary Common Stock Option Exercise-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents56.01
Proceeds From Sale Of Under Controlled Equity Offering Net Of Costs0.73
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.58
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-31.10
Total Cash Flow-20.93
4 historic quarters locked

Sign in to unlock the full Lumos Pharma Inc cash flow history.

Sign In Create Free Account

About Lumos Pharma Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001126234-24-000025

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License